<nav id="0rydl"></nav>

  1. <li id="0rydl"><acronym id="0rydl"></acronym></li>

    <em id="0rydl"></em>
    <rp id="0rydl"></rp>

  2. Language: Chinese | English
    Development

    Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd
    Tel: 0755-26405471
    Fax: 0755-86573069
    E-mail: # @ qq.com
    Company Address: Nanshan District, Shenzhen City Taoyuan Street Tianliao Industrial Zone 9, 2nd Floor, east

    Scientific research direction

    Current position:Home > Development - Scientific research direction

    1, CD3-MUC1 new bispecific antibody development;
    2, CD16-MUC1 new bispecific antibody development;
    3, CD3-MUC1 new bispecific antibody development;
    4, CD3-CD20 new bispecific antibody development;
    5, CD3-HER2 new bispecific antibody development;
    6, CD3-CD38 new bispecific antibody development;
    7, CD3-BCMA new bispecific antibody development;
    8, T cell efficient amplification technique optimization;
    9, NK cell efficient amplification technology optimization;
    10, Targeted activated CIK cells in the treatment of advanced liver cancer randomized, controlled clinical study; cooperation unit: People's Liberation Army 302 Hospital;
    11, targeted MUC1 new bispecific antibody combined with autologous T cells in the treatment of lung cancer clinical research; cooperation unit: Shenzhen People's Hospital;
    12, the new bispecific antibody combined with activated T cells in the treatment of children with refractory leukemia; cooperation unit: Sun Yat-sen Sun Yat-sen Memorial Hospital cooperation.


    欧美日韩国产综合在线_2020无码天天喷水天天爽_色窝窝无码一区二区三区_国产精品 精品